Enzymatic release of a surface-adsorbed RGD therapeutic from a cleavable peptide anchor (Q33369494)

26 July 2017

Enzymatic release of a surface-adsorbed RGD therapeutic from a cleavable peptide anchor (English)

1 reference

26 July 2017

Steven R Meyers

1

0 references

Mark W Grinstaff

object named as

Mark W Grinstaff

series ordinal

3

0 references

author name string

Daniel J Kenan

series ordinal

2

1 reference

26 July 2017

1 November 2008

1 reference

26 July 2017

1 reference

26 July 2017

3

1 reference

26 July 2017

11

1 reference

26 July 2017

1645-1648

1 reference

Narrative review: drug-eluting stents for the management of restenosis: a critical appraisal of the evidence.

26 July 2017

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800205

Biomimetic delivery of keratinocyte growth factor upon cellular demand for accelerated wound healing in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800205

Inhibition of integrin function by a cyclic RGD-containing peptide prevents neointima formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800205

Biomaterials: where we have been and where we are going

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800205

7 January 2021

Coronary stenting and inflammation: implications for further surgical and medical treatment.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800205

7 January 2021

Drug-eluting coronary stents.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800205

7 January 2021

Early experiences and clinical implications of drug-eluting stents: part 1.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800205

7 January 2021

Frontiers in interventional cardiology

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800205

7 January 2021

Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800205

7 January 2021

Peptide-PEG amphiphiles as cytophobic coatings for mammalian and bacterial cells

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800205

7 January 2021

The effect of enzymatically degradable IPN coatings on peri-implant bone formation and implant fixation

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800205

7 January 2021

The effect of enzymatically degradable poly(ethylene glycol) hydrogels on smooth muscle cell phenotype

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800205

7 January 2021

Scaffolds based on degradable alginate hydrogels and poly(lactide-co-glycolide) microspheres for stem cell culture.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800205

7 January 2021

Recombinant gelatin hydrogels for the sustained release of proteins

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800205

7 January 2021

Material properties and cytocompatibility of injectable MMP degradable poly(lactide ethylene oxide fumarate) hydrogel as a carrier for marrow stromal cells.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800205

7 January 2021

Development of enzymatically degradable protective coatings for use in triggered drug delivery systems: derivatized starch hydrogels

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800205

7 January 2021

Polymers containing enzymatically degradable bonds. VI. Hydrophilic gels cleavable by chymotrypsin

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800205

7 January 2021

Biodegradable microspheres of novel segmented poly(ether-ester-amide)s based on poly(epsilon-caprolactone) for the delivery of bioactive compounds

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800205

7 January 2021

Controlled release of a model protein from enzymatically degrading dextran microspheres

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800205

7 January 2021

Hydrophilic matrices to be used as bioactive and degradable bone cements

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800205

7 January 2021

Development of growth factor fusion proteins for cell-triggered drug delivery

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800205

7 January 2021

The enhancement of chondrogenic differentiation of human mesenchymal stem cells by enzymatically regulated RGD functionalities

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800205

7 January 2021

Protease-induced release of functional peptides from bioplexes

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800205

7 January 2021

Transient kinetic studies of pH-dependent hydrolyses by exo-type carboxypeptidase P on a 27-MHz quartz crystal microbalance.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800205

7 January 2021

Real-time surface plasmon resonance imaging measurements for the multiplexed determination of protein adsorption/desorption kinetics and surface enzymatic reactions on peptide microarrays

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800205

7 January 2021

Pseudo First-Order Cleavage of an Immobilized Substrate by an Enzyme Undergoing Two-Dimensional Surface Diffusion

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800205

7 January 2021

Mobility of enzymes on insoluble substrates: the beta-amylase-starch gel system.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800205

7 January 2021

Delivery of large biopharmaceuticals from cardiovascular stents: a review

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800205

7 January 2021

Sustained Local Delivery of Dexamethasone by a Novel Intravascular Eluting Stent to Prevent Restenosis in the Porcine Coronary Injury Model

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800205

7 January 2021

Local methylprednisolone delivery using a BiodivYsio phosphorylcholine-coated drug-delivery stent reduces inflammation and neointimal hyperplasia in a porcine coronary stent model

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800205

7 January 2021

First human experience with the 17-beta-estradiol-eluting stent: the Estrogen And Stents To Eliminate Restenosis (EASTER) trial

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800205

7 January 2021

TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800205

7 January 2021

Early outcome after sirolimus-eluting stent implantation in patients with acute coronary syndromes: insights from the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800205

7 January 2021

A novel drug-eluting stent coated with an integrin-binding cyclic Arg-Gly-Asp peptide inhibits neointimal hyperplasia by recruiting endothelial progenitor cells.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800205

7 January 2021

Physiological transport forces govern drug distribution for stent-based delivery

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800205

7 January 2021

Identifiers

DOI

10.1002/CMDC.200800205

1 reference

26 July 2017

1 reference

PubMed ID

18792896